Form 4: Terns Pharmaceuticals Director Acquires Stock Options

Director Jeffrey B. Kindler acquires 32,000 stock options in Terns Pharmaceuticals.

Summary

• On June 10, 2024, Jeffrey B. Kindler, a director of Terns Pharmaceuticals, Inc., acquired 32,000 stock options.
• The exercise price of these options is $6.99.
• The options vest on the earlier of the first anniversary of the grant date or immediately prior to the next Annual Meeting, and expire on June 9, 2034.
• Following the transaction, Kindler directly owns 32,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director is generally a good sign, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard transaction for directors of publicly traded companies. Stock options are frequently used as part of compensation packages to align the interests of management with those of shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the pharmaceutical industry.
• Comparable companies like Gilead Sciences or Amgen also use stock options as part of their executive compensation packages.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates